GPP
MURA

Great Point Partners’s Mural Oncology MURA Stock Holding History

Great Point Partners’s Portfolio MURA Stock Details MURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11,509
Closed -$68.1K – 38
2023
Q4 		$68.1K Buy
+11,509
New +$46.3K 0.01% 34

Other funds holding MURA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
AFA
Alta Fundamental Advisers New York $265M AUM 98.61% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Great Point Partners's MURA Position: Q1 2024 in Review

Great Point Partners sold out of Mural Oncology (MURA) in Q1 2024, closing a stake of 11,509 shares — an estimated $68.1K sold.

Great Point Partners first reported a position in MURA in Q4 2023 and held it in 1 quarter. The position peaked at $68.1K in Q4 2023. 101 funds tracked by Wall St. Rank hold MURA as of Q1 2024.

  • Great Point Partners reported no remaining Mural Oncology position as of Q1 2024 after selling out during the quarter.
  • Great Point Partners sold 11,509 Mural Oncology shares in Q1 2024, an estimated $68.1K.
  • Great Point Partners first reported a position in Mural Oncology in Q4 2023 and held it in 1 quarter.
  • Great Point Partners's Mural Oncology position peaked at $68.1K in Q4 2023.
  • 101 funds tracked by Wall St. Rank held Mural Oncology as of Q1 2024.

Based on Great Point Partners's 13F filing for Q1 2024, filed 15 May 2024.